Business
Marina Biotech Appoints Chief Legal Officer to Support Legal, Transactional and Intellectual Property Portfolio Initiatives
Marina Biotech Appoints Chief Legal Officer to Support Legal, Transactional and Intellectual Property Portfolio Initiatives.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n\n City of Industry, CA, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that Peter D. Weinstein, Ph.D., J.D. will join the company in the newly created role of Chief Legal Officer to support the Company’s legal, transactional and intellectual property portfolio initiatives, effective immediately. \n Dr. Weinstein has served as Chief Executive Officer of Entralta, P.C., a full service legal and business firm that specializes in working with small companies, since 2012.  Prior to Entralta, Dr. Weinstein served as Senior Counsel at Baxter Healthcare Corporation where he handled legal, intellectual property, transactional and business development matters for Baxter’s major hemophilia products and development programs.  Dr. Weinstein has also served an attorney at Fish & Richardson, Brobeck, Phleger & Harrison and Goodwin Procter and prior to that he was an Examiner with the United States Patent & Trademark Office.  Dr. Weinstein received his law degree from Boston College Law School, Ph.D. in Biology/Immunology from the University of Pennsylvania and a degree in Biology from the University of Connecticut.  Dr. Weinstein is a member of the California Bar and is a registered to practice before the United States Patent & Trademark Office as a Patent Attorney. “We are excited to have Peter join the Marina Biotech team to establish a strong legal and intellectual property organization for Marina Biotech. Peter brings with him over two decades of strong legal, transactional, intellectual property and business experience to the Company,” stated Vuong Trieu, Executive Chairman of Marina Biotech. “Marina Biotech is uniquely positioned to offer a total care platform for hypertensive with the combination of our DyrctAxess platform for drug distribution and anti-hypertensive treatments such as Prestalia.  We look to Peter to expand our patent portfolio protecting DyrctAxess and Prestalia as well as our product pipeline, while also supporting the legal compliance aspects of our business.” Dr. Weinstein stated, “I appreciate the exciting opportunity to work with the leadershi...